138 related articles for article (PubMed ID: 15621804)
21. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
22. Blood or marrow transplantation for mantle cell lymphoma.
Kasamon YL
Curr Opin Oncol; 2007 Mar; 19(2):128-35. PubMed ID: 17272985
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
Robinson SP; Boumendil A; Finel H; Peggs KS; Chevallier P; Sierra J; Finke J; Poiré X; Maillard N; Milpied N; Yakoub-Agha I; Koh M; Kröger N; Nagler A; Koc Y; Dietrich S; Montoto S; Dreger P
Bone Marrow Transplant; 2018 May; 53(5):617-624. PubMed ID: 29335632
[TBL] [Abstract][Full Text] [Related]
24. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.
Champlin R; van Besien K ; Giralt S; Khouri I
Curr Oncol Rep; 2000 Mar; 2(2):182-91. PubMed ID: 11122842
[TBL] [Abstract][Full Text] [Related]
27. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
28. Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12 years after allogeneic transplantation.
Tamaki M; Wada H; Gomyo A; Hayakawa J; Akahoshi Y; Harada N; Kusuda M; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Kikuchi M; Kimura SI; Nakasone H; Kako S; Kanda Y
Int J Hematol; 2018 Jan; 107(1):117-121. PubMed ID: 28685308
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Lin RJ; Ho C; Hilden PD; Barker JN; Giralt SA; Hamlin PA; Jakubowski AA; Castro-Malaspina HR; Robinson KS; Papadopoulos EB; Perales MA; Sauter CS
Br J Haematol; 2019 Mar; 184(6):1006-1010. PubMed ID: 30537212
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
32. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
33. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
34. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
35. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS; Bassett R; Ledesma C; Korbling M; Alousi A; Hosing C; Kebraei P; Harrell R; Rondon G; Giralt SA; Anderlini P; Popat U; Pro B; Samuels B; Hagemeister F; Medeiros LJ; Champlin RE; Khouri IF
Blood; 2009 Apr; 113(18):4144-52. PubMed ID: 19168784
[TBL] [Abstract][Full Text] [Related]
36. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
37. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.
Cassaday RD; Gopal AK
Best Pract Res Clin Haematol; 2012 Jun; 25(2):165-74. PubMed ID: 22687452
[TBL] [Abstract][Full Text] [Related]
39. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic stem cell transplantation in mantle cell lymphoma.
Ganti AK; Bierman PJ; Lynch JC; Bociek RG; Vose JM; Armitage JO
Ann Oncol; 2005 Apr; 16(4):618-24. PubMed ID: 15781489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
